drugset
drugset / Trial / NCT00804687

An Efficacy Study of JNJ-39220675 and Pseudoephedrine in Participants With Allergic Rhinitis

NCT00804687 ↗

Phase 2 Completed 53 enrolled Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
RandomizedCrossoverSingle-blindTreatment

Summary

The purpose of this study is to evaluate the relative efficacy of JNJ- 39220675 and pseudoephedrine compared to placebo (medication with no active ingredients) in participants with allergic rhinitis (inflammation of the nose due to exposure to allergens such as pollen, dust or animal hair).

Timeline

Start
2008-11
Primary completion
2009-02
Completion
2009-02

Outcome

Missed primary endpoint

registry Placebo vs JNJ-39220675; p = 0.0602; Least Squares Mean difference -0.126 (95% CI -0.258 to 0.006) NCT00804687 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject JNJ-39220675 Small molecule 10 mg Oral
Subject Pseudoephedrine Small molecule 60 mg Oral

Indications

allergic rhinitis